Topics
CNS Tumors | Treatment | Immunotherapy | Sotigalimab
Home > Publications > Topics > CNS Tumors > Treatment > Immunotherapy > Sotigalimab
Lindsay HB, Billups CA, Kocak M, Alban TJ, Young Poussaint T, Wong
P, Chan TA, Kovacic B, Makarov V, Juric I, Diaz-Montero CM,
Srivastava R, Pavicic P, Parthasarathy P, Lenzen A, MacDonald TJ,
Pollack IF, Vinitsky A, Robison NJ, Baxter P, Hwang EI, Leggas M,
Khalil DN, Fangusaro J, Onar-Thomas A, Dunkel IJ.
Pediatric
Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab
in pediatric and young adult patients with recurrent CNS tumors
and newly-diagnosed DIPG.
Clin
Cancer Res. 2026 Jun 30. doi:
10.1158/1078-0432.CCR-26-0655. PMID:
42377093. Trial
registration ID:
NCT03389802˰ ˍ